Renata Abrahão1, Raul C Ribeiro2, Daphne Y Lichtensztajn1, Aaron S Rosenberg3, Theresa H M Keegan3. 1. Greater Bay Area Cancer Registry, Cancer Prevention Institute of California, Fremont, California. 2. Department of Oncology and Global Pediatric Medicine, Division of Leukemia and Lymphoma, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Division of Hematology and Oncology, Center of Oncology Hematology Outcomes Research and Training, University of California Davis School of Medicine, Sacramento, California.
Abstract
BACKGROUND: This population-based study considered the influence of rituximab on the survival of children (0-19 years), adolescents, and young adults (AYAs, 20-39 years) with diffuse large B-cell lymphoma (DLBCL), including patients with human immunodeficiency virus (HIV) infection. METHODS: Data on 642 children and AYAs diagnosed with DLBCL during 2001-2014 were obtained from the Greater Bay Area Cancer Registry in California. Facility-level reports provided treatment details. The Kaplan-Meier method estimated survival and Cox regression models examined the association between survival and rituximab use, adjusting for sociodemographic and clinical factors. RESULTS: Rituximab use increased from 2001-2007 to 2008-2014 among children (from 32% to 48%), AYAs (from 68% to 84%), and HIV patients (from 57% to 67%). Five-year survival was higher among children (91%) than AYAs (82%). On multivariable analysis, the hazard of death was 44% lower among rituximab recipients, and higher among uninsured patients, those with HIV, and those with advanced stage at diagnosis. HIV patients who received rituximab were 60% less likely to die than nonrecipients. CONCLUSIONS: Our study suggests a benefit of rituximab on the treatment of AYAs and HIV patients with DLBCL. The worse survival observed among HIV-positive and uninsured patients is of concern and calls for further investigation. Careful consideration should be given on whether to recommend rituximab more often on the front-line treatment of children and HIV-positive patients with DLBCL.
BACKGROUND: This population-based study considered the influence of rituximab on the survival of children (0-19 years), adolescents, and young adults (AYAs, 20-39 years) with diffuse large B-cell lymphoma (DLBCL), including patients with human immunodeficiency virus (HIV) infection. METHODS: Data on 642 children and AYAs diagnosed with DLBCL during 2001-2014 were obtained from the Greater Bay Area Cancer Registry in California. Facility-level reports provided treatment details. The Kaplan-Meier method estimated survival and Cox regression models examined the association between survival and rituximab use, adjusting for sociodemographic and clinical factors. RESULTS: Rituximab use increased from 2001-2007 to 2008-2014 among children (from 32% to 48%), AYAs (from 68% to 84%), and HIV patients (from 57% to 67%). Five-year survival was higher among children (91%) than AYAs (82%). On multivariable analysis, the hazard of death was 44% lower among rituximab recipients, and higher among uninsured patients, those with HIV, and those with advanced stage at diagnosis. HIV patients who received rituximab were 60% less likely to die than nonrecipients. CONCLUSIONS: Our study suggests a benefit of rituximab on the treatment of AYAs and HIV patients with DLBCL. The worse survival observed among HIV-positive and uninsured patients is of concern and calls for further investigation. Careful consideration should be given on whether to recommend rituximab more often on the front-line treatment of children and HIV-positive patients with DLBCL.
Authors: Stefan K Barta; Xiaonan Xue; Dan Wang; Roni Tamari; Jeannette Y Lee; Nicolas Mounier; Lawrence D Kaplan; Josep-Maria Ribera; Michele Spina; Umberto Tirelli; Rudolf Weiss; Lionel Galicier; Francois Boue; Wyndham H Wilson; Christoph Wyen; Albert Oriol; José-Tomás Navarro; Kieron Dunleavy; Richard F Little; Lee Ratner; Olga Garcia; Mireia Morgades; Scot C Remick; Ariela Noy; Joseph A Sparano Journal: Blood Date: 2013-09-06 Impact factor: 22.113
Authors: Kieron Dunleavy; Richard F Little; Stefania Pittaluga; Nicole Grant; Alan S Wayne; Jorge A Carrasquillo; Seth M Steinberg; Robert Yarchoan; Elaine S Jaffe; Wyndham H Wilson Journal: Blood Date: 2010-02-03 Impact factor: 22.113
Authors: Xuesong Han; Ahmedin Jemal; Erin Hulland; Edgar P Simard; Loretta Nastoupil; Elizabeth Ward; Christopher R Flowers Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-10-18 Impact factor: 4.254
Authors: Elizabeth Ward; Michael Halpern; Nicole Schrag; Vilma Cokkinides; Carol DeSantis; Priti Bandi; Rebecca Siegel; Andrew Stewart; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2007-12-20 Impact factor: 508.702
Authors: Thomas S Uldrick; Gwynn Ison; Michelle A Rudek; Ariela Noy; Karl Schwartz; Suanna Bruinooge; Caroline Schenkel; Barry Miller; Kieron Dunleavy; Judy Wang; Jerome Zeldis; Richard F Little Journal: J Clin Oncol Date: 2017-10-02 Impact factor: 44.544
Authors: Theresa H M Keegan; Lynn A G Ries; Ronald D Barr; Ann M Geiger; Deborah Vollmer Dahlke; Bradley H Pollock; W Archie Bleyer Journal: Cancer Date: 2016-02-05 Impact factor: 6.860
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J A Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Date: 2021-09-28 Impact factor: 2.984